Morcellation Cancer Lawsuit
Morcellation cancer lawsuits are being filed by attorneys across the nation for women whose cancer has been worsened following surgery of the uterus. Laparoscopic Power Morcellation is a procedure used for removal of the uterus (hysterectomy) or to remove uterine fibroids (myomectomy). The morcellator machine basically fragments the tissue so that it can be removed through a small incision.
Why are Morcellators a Problem?
The problem with power morcellation is that if the patient has cancerous tissue the procedure then spreads cancerous cells throughout the patient’s abdomen and significantly decreases her long term survival. Women with previously unknown uterine sarcoma cancer such as;
- leiomyosarcoma or (LMS)
- endometrial stromal sarcoma
- parasitic myoma
should seek legal advice if they previously had any type of uterine surgery. As warned by the US Food and Drug Administration (FDA), this significantly reduces the chance of long-term survival. Also, even insurance companies have now refused to pay for the use of these dangerous devices.
FDA data estimates that 1 in 350 women undergoing a hysterectomy or myomectomy for treatment of fibroids is later diagnosed with a previously unsuspected uterine sarcoma (cancer), including leiomyosarcoma and parasitic myoma. According to the FDA;
Uterine tissue may contain unsuspected cancer. The use of laparoscopic power morcellators during fibroid surgery may spread cancer and decrease the long-term survival of patients. This information should be shared with patients when considering surgery with the use of these devices.
Uterine Cancer Lawsuit
Uterine morcellator cancer lawsuits are being filed by women who underwent uterus surgery and found that the surgery itself caused pre-existing cancer (known or unknown) to spread to other parts of the body.
Hysterectomy and Myomectomy Cancer Lawsuits
Cancer following a hysterectomy may be caused or worsened by the surgery itself according to warnings issued by the United States Food and Drug Administration (FDA). This has resulted in many cases for compensation being filed around the country on behalf of women and their families whose cancer has been aggravated by certain uterus surgeries such as hysterectomies or uterine fibroid (Myomectomy) removal.
Leiomyosarcoma (also known as LMS) is a relatively rare but unpredictable form of uterine sarcoma cancer. Recently, following FDA warnings, lawsuits have been filed because women had discovered they have the cancer following uterus surgery such as for the removal of uterine fibroids (myomectomy) or hysterectomy.
Parasitic Myoma – Morcellation Claims
Lawsuits are being filed across the country on behalf of women who submitted to certain gynecological surgical procedures through laparoscopic power morcellation and were later diagnosed with uterine cancer. Current FDA data estimates that 1 in 350 women undergoing a laparoscopic supracervical hysterectomy, laparoscopic myomectomy, or laparoscopic total hysterectomy for treatment of fibroids is later diagnosed with a previously unsuspected uterine sarcoma (cancer), including leiomyosarcoma.